RE:Short vol low... Speculation is the game here. I don't know what will happen once they are listed
Looking at the facts, April listing would be beneficial because they can announce Q4 results after. The big news will be if treosulfan is approved for sale in US by FDA which I believe it will.
As for the company itself: YoY nearly doubled revenue, lots of cash on hand , reduced Admin and selling costs, adj. EPS was (500,000) vs (5.2M) over same period last year, Ebitda $5.1M vs $0.5M over same period last year. Etc... and all good news as per their Q3 earnings release.
The key point of listing on the Nasdaq was to get exposure into the market that derive most of their revenue. I would assume this is so the price per share would go up so if need they could do a PP for more acquistions of distribution agreements.